Ir para o conteúdo principal

Nuvation Bio (NYSE: NUVB) — Perfil da empresa, notícias e dados financeiros

Logo de Nuvation Bio
NUVB Nuvation Bio
Nuvation Bio primary media
Perfil da empresa

Nuvation Bio

Nuvation Bio (NYSE:NUVB) is a biotechnology firm engaged in the discovery, development, and commercialization of innovative oncology treatments. With a focus on bringing novel solutions to patients suffering from cancer, Nuvation Bio is actively working on a portfolio of promising projects aimed at addressing some of the most challenging diseases. Their objectives include advancing cancer treatment options through clinical trials, leveraging cutting-edge science to uncover new therapy pathways, and ultimately improving patient outcomes. The company's dedicated team of scientists and researchers are committed to pushing the boundaries of what's possible in cancer care, driven by a passion to make a significant difference in the lives of those affected by this devastating disease.

Resumo

Public USParticipação acionária
2018Ano de fundação
51Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de Nuvation Bio

  • Development of innovative oncology treatments targeting various cancers, focusing on unmet medical needs.
  • Research on bi-specific antibodies aimed at improving the precision and effectiveness of cancer immunotherapies.
  • Advancement of small molecule therapeutics designed to inhibit cancer cell proliferation and survival.
  • Creation of a novel protein degradation platform to target and destroy cancer-causing proteins.
  • Exploration of targeted radiotherapy solutions for precise delivery of radiation to cancer cells, minimizing damage to healthy tissues.
  • Investigation into cell therapy techniques for cancer treatment, emphasizing the engineering of immune cells to better recognize and eliminate cancer cells.

equipe executiva do Nuvation Bio

  • David T. HungFounder, President, CEO & Chairman
  • Philippe Pierre SauvageCFO & Principal Financial Officer
  • Gary HattersleyChief Scientific Officer
  • Moses MakunjeVP of Finance and Principal Accounting & Financial Officer
  • David C. HanleyChief Technical Operations Officer
  • Robert DeVitaVice President of Corporate Development & Investor Relations
  • Stephen DangChief Legal Officer & Corporate Secretary
  • Stacy MarkelChief People Officer
  • Kerry A. WentworthChief Regulatory Officer
  • Colleen SjogrenChief Commercial Officer

Principais indicadores financeiros

Resultados divulgados pela Nuvation Bio, em USD.

Cap. de mercado
1,6 bi
Receita (TTM)
169,9 mi
P/L
—
LPA (diluído, TTM)
-0.4
Dividend yield
—
Margem de lucro
-88.2%
Receita e lucro anuais da Nuvation Bio
Fim do ano fiscalReceitaResultado operacionalLucro líquido
62,9 mi-213,1 mi-204,6 mi
7,9 mi-592,6 mi-567,9 mi
0-99,8 mi-75,8 mi
0-119,7 mi-104,2 mi